Agilus Diagnostics IPO Details
MAINBOARD
Agilus Diagnostics IPO DRHP (Draft Red Herring Prospectus) has been Filed With SEBI.
Pre-issue shareholding stands at 7,84,25,542, which will increase to 7,84,25,542 post-issue.
The Lead Managers for Agilus Diagnostics IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Axis Capital Limited, ICICI Securities Limited, Citigroup Global Markets India Private Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Agilus Diagnostics Limited DRHP.
Agilus Diagnostics IPO Details
Agilus Diagnostics IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Agilus Diagnostics IPO Reservation
Promoter Holding
Documents
Agilus Diagnostics IPO Valuations
To be announced
Agilus Diagnostics Financial Information
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 2,418.74 | 2,279.96 | 1,586.31 |
| Total Income | 1,371.10 | 1,618.35 | 1,060.69 |
| Profit After Tax | 116.64 | 554.71 | 131.25 |
| Net Worth | 1,945.58 | 1,866.15 | 1,311.38 |
| Reserves and Surplus | 1,867.15 | 1,787.73 | 1,232.96 |
| Total Borrowing | 1.25 | 2.25 | 2.83 |
| Amount in ₹ Crore | |||
About Agilus Diagnostics IPO
Agilus Diagnostics Limited, incorporated in 1995, provides diagnostic testing services, including routine and specialized tests, wellness and preventive care packages, hospital laboratory management services, and clinical research trial testing services.
As of March 31, 2023, the company operated a network of 413 laboratories, with 43 laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
Agilus Diagnostics Limited maintains an international presence across regions including the Middle East, Sub-Saharan Africa, the Commonwealth of Independent States, and the South Asian Association for Regional Cooperation (SAARC).
During the fiscal year 2023, the company conducted 39.07 million tests and served 16.62 million patients in India and internationally.
The diagnostics network spans 25 Indian states and five union territories, covering over 1,000 towns and cities and more than 532 districts. The network follows a hub-and-spoke model and includes one central global reference laboratory in Mumbai, five regional reference laboratories, and 407 other clinical laboratories, comprising pathology and radiology centers.
Agilus Diagnostics Limited also operates 25 wellness centers, three Centers of Excellence, 3,757 customer touch points such as patient service centers and collection centers, and over 12,000 pick-up points serving institutional clients.
The test portfolio consists of over 3,600 routine and specialized diagnostic tests and wellness packages across various medical specialties.
The company provides services to both individual patients (B2C) through walk-in centers, home collection services in over 80 cities, and digital platforms, and institutional customers (B2B), including physician offices, hospitals, laboratories, radiology centers, corporate employers, insurance companies, public-private partnerships, and clinical research organizations.
As of March 31, 2023, we had a total of 7,061 employees, including 438 doctors, 4,176 technicians and paramedical staff and 2,447 support staff located in India, and 84 full-time employees located outside India.
Competitve Strenghts:
- Experienced pan-India diagnostics service provider with a diversified presence and a growing network that is well positioned to capitalize on the expected growth in the Indian diagnostics industry.
- Comprehensive test offerings providing one stop solution for diagnostic requirements.
- Advanced information technology platform supported by integrated systems enabling customer-centric initiatives.
- Well-balanced B2C and B2B revenue mix.
- Quality network of accredited laboratories supported by R&D capabilities focused on genomics and next-generation diagnostics.
- Strong parentage and experienced management team with significant industry experience.
Strength Of Agilus Diagnostics IPO
Risk Of Agilus Diagnostics IPO
Objectives Agilus Diagnostics IPO
To be announced
Company Contact Details
Agilus Diagnostics Ltd.
Fortis Hospital,
Sector 62,
Phase – VIII,
Mohali, Punjab, 160062
Phone: 0124-6261111
Email: investors@agilus.in
Website: http://www.agilusdiagnostics.com/
Registrar Contact Details
Read more about Agilus Diagnostics Limited IPO
- Agilus Diagnostics Limited IPO Detail
- Agilus Diagnostics Limited IPO Subscription Detail
- Agilus Diagnostics Limited IPO GMP Detail
- Checked Live Agilus Diagnostics Limited IPO Allotment Status
- Agilus Diagnostics Limited IPO Basis Of Allotment
- Agilus Diagnostics Limited IPO Price Calculator
- Agilus Diagnostics Limited IPO Stock Price
